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Abstract 
Objective 
Recent research indicates considerable heterogeneity in the provision of memory 
assessment services (MAS). However, little is known on the extent of variation in the costs 
of the services MAS provide. We investigated the costs of supporting patients with 
suspected dementia, including assessment and support over the following six months.  
Methods 
Clinic costs were estimated on the basis of an organisational survey reporting staff roll, 
grade and activities. Costs of primary health and social care were estimated from 
questionnaire data reported by carers of patients at baseline, three and six months after 
referral. 
Results 
Mean monthly staff costs at MAS were £73,000. Imaging at assessment cost an additional 
£3,500 per month. Monthly clinic cost per new patient assessed varied from £320 to £5,400 
across clinics. Additional primary health and social care costs of £130-220 a month between 
baseline and six months were reported by carers. Costs of pharmacological and non-
pharmacological treatments reported by carers were small. Informal care costs dwarfed 
health and social care costs when valued at a modest unit cost. The overall mean cost of 
supporting a patient for six months varied from £1,600 to £2,500 dependent on 
assumptions regarding the proportion of MAS intervention and review costs accrued at six 
months.  
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Conclusions 
There is considerable variation in the intensity and associated costs of services provided by 
MAS. Further research should ascertain to what extent such variation is associated with 
differences in patient outcomes. 
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Introduction 
Timely diagnosis of dementia is central to the English Government’s strategy to deliver 
world class dementia care (Department of Health, 2009). Timely diagnosis allows treatment 
which may slow the progress of the disease and provision of psychosocial support for 
patients and their family or unpaid carers (hereafter ‘carers’) (National Institute of Health 
and Care Excellence, 2016). In England, most people are assessed and diagnosed in Memory 
Assessment Services (MAS) which also provide or provide access to post-diagnostic support 
(Hodge & Hailey, 2015). The evolution of MAS in England has been haphazard. Clinical 
guidelines on their structure and role were not published until 2011 (Doncaster et al. 2011). 
The resulting plethora of different service models partly reflects the lack of evidence 
regarding the relative effectiveness of different approaches (Kelly, 2008).  
Whilst there is a consensus that MAS improve outcomes, evidence on the relative 
effectiveness of different models of service delivery is very limited (Melis et al. 2009). In the 
Netherlands, the AD-EURO study, which randomised 175 patients to support by either a 
MAS or general practitioner (GP), found no significant difference in health-related  quality of 
life (HRQL) or carer burden (Meeuwsen et al. 2012). The PLASA study randomised 1131 
patients to receive either a comprehensive care plan or treatment as usual from their MAS 
(Nourhashemi et al. 2010). No significant differences in functional decline or ability to 
undertake daily activities were observed. MAS have been criticised for excessive use of 
imaging, over-reliance on consultants for diagnosis, and a focus on drug treatment rather 
than holistic care (Pelosi et al. 2006). 
Evidence on the cost of MAS is equally limited. Data from a survey of MAS in England 
indicated national expenditure of £125million in 2014 (Hodge & Hailey, 2015). A recent UK 
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study compared the costs of diagnosis and post-diagnostic support in 33 patients attending 
a MAS and 33 patients diagnosed by their Community Mental Health Team (Rubinsztein et 
al. 2015). Mean cost for patients attending the MAS (£742 - 2010 GBP) was marginally 
lower. The increased use of nurses and allied health professionals in place of doctors has 
been suggested to reduce costs of MAS (Bentley et al. 2014; Page et al. 2008). 
A companion paper has reported the results of an extensive organisational survey of 78 
MAS in England and found considerable variation in staff numbers, workload, skill-mix and 
activities (Chrysanthaki et al. 2016). Our aim here was to estimate the cost of diagnosis and 
initial post-diagnostic services for patients attending a representative sample of MAS across 
England. Costs of diagnosis are estimated on the basis of staff numbers and activity 
reported by MAS in the organisational survey, along with costs of primary health and social 
care following diagnosis estimated from resource use reported by carers. 
Methods 
Study design and inclusion criteria 
We recruited 80 MAS at random, selected from the Memory Services Register compiled by 
the Royal College of Psychiatrists. Each site was expected to recruit 25 patients together 
with their carers if the patient was accompanied. Two sites subsequently withdrew, five 
sites were excluded having recruited fewer than six patients, and four sites were excluded 
after failing to collect outcome data at six months, leaving a final sample of 69. Patients 
were eligible for the study if they spoke English and were attending the MAS as part of their 
first assessment. At baseline and 6 month follow up (either at clinic or home visit), carers 
completed questionnaires on resource use and HRQL, which included EQ-5D-3L-Proxy 
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(Brooks, 1996) and DEMQOL-proxy (Smith et al. 2007). Resource use was also collected at 
three months. Patients also completed HRQL questionnaires (EQ-5D and DEMQOL)  at 
baseline and 6 months.  The three-month follow-up questionnaires were mailed to carers 
with a reminder if a response was not received within 4 weeks.  All participants were 
followed up regardless of the diagnosis they received. Data collection commenced in 
September 2014 and patient recruitment ended in May 2015. An organisational survey was 
completed by each MAS in March 2015 using a mailed questionnaire to the lead contact 
with telephone follow-up to maximise response rate (Chrysanthaki et al. 2016).  
The study was approved by the National Research Ethics Service Committee London 
(reference: 14/LO/1146) and the London School of Hygiene & Tropical Medicine ethics 
committee (reference: 8418). 
Questionnaires 
Each MAS was asked to provide a list of staff employed in the week the questionnaire was 
completed, along with their grade, proportion of a full time week they worked and 
proportion of their time spent in different activities (assessment, interventions and follow-
up). The organisational survey also collected data on brain imaging used in assessment and 
review. 
Resource use data were collected from patients’ carers at baseline and at three and six 
month follow-up using a modified version of the Client Services Receipt Inventory (Beecham 
& Knapp, 2001). The questionnaire asked about resource use in the previous month 
including: primary health care; social care; unpaid (informal) care; travel time to the MAS; 
social security benefits; personal budgets; drugs prescribed for the patient’s cognitive 
condition; and psychosocial support services relevant to their condition such as cognitive 
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stimulation therapy (CST). Data on hospital inpatient episodes were not included given the 
difficulty of establishing whether it was attributable to dementia. We also chose not to 
collect residential care costs on the assumption that most new patients would be living in 
their own homes.   
Costs 
Unit costs for health and social care professionals were derived from national cost sources 
for the financial year 2013/14 (or inflated to 2013/14 price levels using the Hospital and 
Community Health Services Index (Curtis, 2014)). Cost of staff employed by MAS including 
on-costs, qualifications, overheads and capital overheads, were estimated from Curtis 
(2014), adjusting to reflect Agenda for Change mid-band salaries according to reported staff 
grade. Imaging costs were taken from NHS reference costs (Department of Health, 2014). 
NHS reference costs were used to assess the cost of patients’ contacts with: community 
district nurse; community psychiatric nurse; psychiatrist/neurologist; psychologist, 
physiotherapist, occupational therapist; dietician; speech and language therapist; Dementia 
advisor/Admiral Nurse (Department of Health, 2014). Unit costs of contact with GPs, 
practice nurses, social workers, and mental health team workers were obtained directly 
from nationally reported costs (Curtis, 2014) or in combination with estimates of contact 
time of 15 minutes for a practice nurse (Shum et al. 2000), and 20 minutes for a social 
worker (Davey et al. 2005). Unit costs of social care such as meals on wheels, sitting services 
and laundry services were derived from national sources (Curtis, 2014) or from an 
evaluation of befriending services for patients with dementia (Charlesworth et al. 2008). 
Drug costs were obtained from the British National Formulary, volume 66 
(http://www.bnf.org/products/bnf-online/). Unpaid care and travel time to MAS for carers 
8 
 
was costed at £6 per hour based on an opportunity cost assumption, using the national 
minimum wage for 2013/14. Other travel costs were not included. 
Costs of psychosocial support were taken from different sources: CST and  befriending 
services (Curtis, 2014);  music/dance therapy (Coulton et al. 2015); animal assisted therapy 
/art therapy (Uttley et al. 2015); life story work/psycho-education/reminiscence therapy 
(Woods et al. 2012);  social engagement groups/peer support groups (Banerjee et al. 2013); 
walking groups (Gusi et al. 2008); and Memory Café ( Curtis 2014) assuming employment of 
one mental health nurse and one administrator per five patients. 
Statistical analysis 
We report estimates of total monthly costs of MAS, and breakdown of costs across 
assessment, post-diagnosis support and follow-up. We report overall costs and costs per 
new patient assessed. Allocation of staff costs was undertaken for each staff member on the 
basis of proportion of time spent in each of: assessment, post-diagnosis support, follow-up, 
administration, management, audit and research. Costs for administration, management 
and audit were aggregated and assigned between assessment, post-diagnosis support and 
follow-up based on relative proportions of time spent on each activity. Costs associated with 
research were ignored. 
We report resource use additional to MAS at baseline, three and six months derived from 
carer questionnaires and the associated monthly costs. We ignored costs of psychosocial 
interventions reported by a carer where the relevant MAS reported providing such an 
intervention as the costs were already included in overall MAS costs. Costs falling on health 
and personal social services (excluding benefit payments) are summed and reported as costs 
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of formal care. Societal costs include costs of formal care, informal care and patient travel 
costs.    
Finally, we estimate the cost of assessment and support over six months following the first 
appointment from a health and personal social services perspective. MAS costs are 
estimated as the assessment costs (including diagnostic investigations) per new patient and 
some proportion of the post-diagnosis support and follow-up costs. We had insufficient data 
to determine the proportion of all interventions and follow-up appointments provided by 
MAS which are delivered within the first six months and consequently we explored the 
impact of varying the proportions from 0 – 100%. Additional health and social care costs 
over the six month period are estimated as three times the monthly cost derived from the 
carer questionnaires at three months plus three times the monthly cost at six months. 
Missing data in both MAS-level and patient-level costs were handled with multiple 
imputation using chained equations (MICE) and 50 imputations (White et al. 2011).  Multiple 
imputation assumes that, conditional on the variables included in the imputation model, the 
probability of observing the cost data is independent of unobserved values, i.e. data are 
missing at random. We implemented a multilevel approach to multiple imputation in R (R 
Core Team, 2013) to recognise the hierarchical structure of the data; patients were 
clustered within MASs and costs were missing at distinct, patient and MAS levels 
(van Buuren, 2011). We report mean costs, median costs and associated measures of 
variance by combining the multiple imputed datasets using Rubin's rules (Rubin, 1987). 
Descriptive statistics were generated in Stata version 14 (StataCorp, 2015). 
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Results 
Recruitment and response rates 
1420 patients from 73 MAS were recruited into the study at baseline of which 1353 were 
from the 69 MAS included in this analysis. We excluded a further 35 patient who died during 
the six month follow-up leaving a final sample of 1318 patients. Mean patient age was 78 
(range 42-98). Less than 1% of participants were resident in care homes at assessment; 690 
(52%) were female and 1235 (94%) were identified as White British; 944 (72%) patients 
were accompanied by a carer, generally a spouse (571) or child (270); 910 (96%) carers 
provided resource use data at baseline. Further data on patients recruited into the study is 
reported elsewhere (Park et al. 2016). 
Resource use responses were received from 617 at three months and 586 at six months. At 
six months, data on diagnosis was available for 825 patients, 441 (53%) diagnosed with 
dementia, 202 (24%) with mild cognitive impairment, 44 (5%) with other mental health 
conditions, and the remainder (17%) yet to receive a diagnosis. 
Missing data 
Missing responses on the carer questionnaire were consistently low (Table 1). Very few 
patients reported receipt of a personal budget and services purchased with the budget were 
poorly reported so this resource use was ignored. With regard to the organisational survey, 
staff employed were reported by 61 (88%) of the 69 MAS and the number of new patients 
assessed was reported by 68 (99%). However, there was considerable missing data for the 
allocation of staff time across clinical activity categories. 
<Table 1 here> 
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Resource use by MAS 
All MAS employed doctors and nurses but the number of whole time equivalents varied 
considerably (Table 2). The most common category of employee was nurses. A typical MAS 
assessed around 50 patients a month but this varied from 10 to 130. Thirty-six (52%) MASs 
reported using imaging at assessment and 5 (7%) at review. 
<Table 2 here>  
Resource use reported by carers 
The most frequently contacted health care professionals were GPs and nurses, though these 
contacts may have been unrelated to cognitive function (Table 1). Around 17% of patients 
reported contact with a psychiatrist or neurologist at both baseline and six month follow-up. 
Contact with other health care professionals was less than 10% at any follow-up. At 
baseline, use of drugs for cognitive decline was rare but increased to around a third of 
patients at three and six months. 
Around 16% of respondents reported receiving the services of a cleaner and around 11% 
received some form of home care support. Around 9% reported contact with a social worker 
at 3 and 6 months. Use of other forms of social care was low. 
At baseline and follow-up use of psychosocial support was rare with the exception of social 
engagement groups. At six months, most patients (359, 63%) had not received any 
pharmacological or non-pharmacological intervention in the previous month. (Note that not 
all patients had been diagnosed with dementia).  
At baseline 31% of patients reported receiving either personal independence payment, 
attendance allowance or disability allowance. This increased to 40% by 6 months. Virtually 
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all patients were receiving informal care at baseline and at each follow-up, around 60 hours 
at all time points. 
Costs 
Table 3 reports the monthly costs of MAS after imputation of missing data. These are 
disaggregated into categories: imaging; assessment; post-diagnostic support; and review 
(follow-up). Slightly under half of all costs were attributed to assessment. The proportion of 
MAS resources attributed to post-diagnostic support varied from 4-54% and the proportion 
attributed to follow-up varied from 6-67%.  
<Table 3 here> 
Across MAS, total monthly costs attributable to assessment activities varied from £2,138 to 
£141,156 driven primarily by the number of staff employed. Variation was reduced but still 
considerable when costs per new patient were calculated. Figure 1 displays the distribution 
of total monthly MAS cost per new patient assessed (including imaging costs). Costs varied 
from £317 to £5408. Costs per new patient for 58 (84%) of the MASs were £500 to £3,000. 
<Figure 1 here> 
Table 4 shows the costs of additional health and social care reported by carers after 
imputation of missing data and after excluding psychosocial support that may have been 
provided by MAS. Cost of drugs for cognitive function was small, as was cost of psychosocial 
support. Societal costs were dominated by informal care. Figure 2 displays the distribution 
of health and social care costs reported by carers at baseline, three and six months. The 
increase in mean costs at six months is driven by a general shift to higher expenditure 
amongst respondents rather than an increase in high cost outliers.  
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<Table 4 here> 
<Figure 2 here> 
Table 5 reports estimated mean costs of imaging, diagnosis, post-diagnosis support and 
follow-up (review) per patient over six months for a patient referred to MAS and including 
additional health and social care costs reported by carers. Dependent on assumptions 
regarding accrual of post-diagnosis support and follow-up costs over time, mean costs 
varied from £1,582 to £2,497. Assuming that 50% of post-diagnosis support activity and 50% 
of follow-up activity undertaken for all patients is undertaken in the first six months 
following assessment, mean cost per new patient is £2,039 and median cost is £1,399. 
<Table 5 here> 
Discussion 
The monthly mean cost of services directly provided by MAS per new patient assessed is 
estimated to be £1,855. Half of this was attributable to assessment costs of which imaging 
costs represented about a tenth. Carers reported additional formal care costing £127-224 a 
month. The combined costs of services provided by MAS and by other formal services over 
the first six months following assessment ranged from £1582 to £2497, dependent on 
assumptions regarding the proportion of all post-diagnostic support and follow-up costs 
accrued at 6 months. The cost of informal care was considerable, despite valuation using a 
conservative unit cost. There was no evidence that MAS attendance decreased informal 
care provision. However, the psychological strain of providing such care may have been 
ameliorated. 
14 
 
There was 17-fold differences in the cost of MAS per patient assessed which arose from 
variation in staff to patient ratios. Extreme values may have arisen from under-reporting of 
staff or the number of patients assessed. Nevertheless, it appears that there is marked 
variation in intensity of MAS activity undertaken to assess and follow-up patients. In 
contrast, provision of psychosocial support following assessment was limited with most 
carers reporting that patients received none. Carers may have failed to recognise support 
such as CST or reminiscence therapy as distinct interventions. It is also possible that the 
follow-up periods (which collected resource use in the third and sixth months) failed to 
cover the period of most intense provision of psychosocial support. Variation in case-mix 
may explain some of the variation in costs across MAS but it is unlikely that case-mix 
explains the large variation in assessment costs observed. This variation is also not explained 
by differences in provision of psychosocial support as only a small proportion of patients 
receive them.  
Comparison with previous research 
Our estimate of mean monthly staff costs for a MAS of £73,000 is considerably higher than 
the £46,000 derived from a survey conducted in 2014 (Hodge & Hailey, 2015). These 
authors reported a mean of 48 new patients assessed per MAS per month, similar to the 
mean number we observed. Our costs were estimated from staff costs published by the 
Personal Social Services Research Unit which include elements for training and gaining 
qualifications, and capital overheads (building construction); these elements account for 
approximately 20% of the total costs (Curtis 2014). These costs are unlikely to be met from 
annual MAS budgets and would explain much of the difference between our costs and those 
reported by the previous survey. The monthly cost of a MAS in Croydon, including capital 
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overheads, has been estimated at about £71,000 and £1,200 per patient assuming 59 new 
patients a month (Curtis, 2014). 
Our estimates of overall mean cost of supporting a patient for six months including and 
following initial assessment is higher than the  £742 (2010/11 GBP) reported by Rubinzstein 
et al (2015). That was a small study and appears to have excluded primary care contacts. 
Our estimate of assessment costs are higher than the mean overall assessment costs 
reported for patients in Sweden but are similar to the mean cost of €1,067 for patients 
referred to specialist services (Jedenius et al. 2010). Cross-country comparisons are hard to 
interpret, however, given often very different treatment and care systems. Assessment and 
support costs over 12 months of €38,000 (2005 Euros) have been reported (Wolfs et al. 
2009) for patients with dementia in the Netherlands. However, that study included sizeable 
residential care, day care and secondary care costs which we chose not to include. 
Study strengths and limitations 
This is the largest and most detailed study to date which has examined the costs of MAS and 
the interventions provided to patients based on a representative sample of MAS in England. 
There are several limitations. First, given the size of the study, we could not micro-cost MAS. 
Instead, we sought to estimate costs based on staff employed. This approach is inevitably 
less accurate than micro-costing. Second, we were dependent on the quality of reporting by 
those completing the MAS survey and we cannot be certain that all staff employed were 
recorded. However, mean WTE observed across MASs closely matched the assumption of 
10 WTE per MAS in an English cost-effectiveness analysis (Banerjee and Wittenberg, 2009). 
Third, we were unable to explore the variation in cost arising from differences in patient 
characteristics. Such a study would have required detailed observation of patient contact 
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with MAS which would have proved very challenging to collect in our large, representative 
sample of MAS.  
Fourth, we had some missing data at both MAS and patient level. We applied a principled 
approach, multiple imputation, to deal with this rather than relying on ad hoc assumptions. 
We also used a sophisticated multi-level approach to imputation to recognise that the 
reasons for the missing data at the patient and MAS levels were distinct, and the possible 
clustering of patients within MAS. Fifth, we relied on questionnaires completed by carers to 
estimate additional costs of health and social services provided outside MAS. Many of these 
costs will be attributable wholly or partially to causes other than cognitive impairment. We 
could not isolate costs attributable to the latter. Asking carers to identify relevant costs 
risked exacerbating the burden of completing the questionnaire and reducing sensitivity to 
changes in resource use associated with general health and wellbeing but influenced by 
MAS. Finally, the data we collected on psychosocial support provided by MASs did not allow 
us to assess intensity of provision of these services.  
Conclusion 
The cost to the health and social care sectors of initial assessment and support of patients 
over the following six months was £1,582 to £2,497, of which approximately half arises from 
services directly provided by a MAS. The cost of pharmacological treatment is low due to 
low unit costs. The cost of psychosocial support (non-pharmacological treatment) is modest 
due to low intensity of use. There is considerable variation in costs across MASs which 
appears to be due to marked differences in workload per staff member. The impact and 
cost-effectiveness of assessment and interventions will be reported in subsequent papers. 
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Tables 
Table 1: Primary health, social care and psychosocial support reported by carers 
 Baseline 
(n = 932) 
Follow up 
 3 months (n = 620) 6 months (n = 587) 
Resource Proportion 
reporting 
contact 
(%) 
Proportion 
missing 
data (%) 
Proportion 
reporting 
contact 
(%) 
Proportion 
missing 
data (%) 
Proportion 
reporting 
contact 
(%) 
Proportion 
missing 
data (%) 
Health care 
General Practitioner 48.1 3.3 36.3 6.0 39.1 2.7 
Practice Nurse 26.2 4.3 20.7 6.0 25.1 4.1 
District Nurse 8.1 4.9 7.5 6.6 9.4 5.3 
Specialist Nurse 1.6 4.2 1.9 5.8 3.1 3.8 
Community Mental 
Health Nurse 10.3 4.1 6.8 6.3 4.6 4.9 
Psychiatrist/ neurologist 17.6 3.6 12.2 5.5 17.1 4.6 
Psychologist 1.0 4.6 2.8 6.0 2.2 4.3 
Physiotherapist 5.6 3.8 5.3 5.5 4.1 4.4 
Occupational Therapist 2.7 3.7 5.2 5.2 3.9 3.4 
Dietician 1.3 4.3 1.8 5.7 0.3 3.6 
Counsellor 0.3 4.0 0.5 6.5 0.0 3.8 
SALT 0.7 4.0 0.6 5.8 0.7 3.6 
Mental health team 
worker 3.6 4.2 3.2 6.0 1.7 3.9 
Dementia Adviser 1.3 4.6 5.2 5.3 4.6 3.8 
Anti-dementia drugs 1.1 11.2 31.6 4.4 33.4 8.4 
Social care 
Social worker 4.1 4.1 9.6 5.8 8.4 3.6 
Home care 10.5 3.1 9.9 3.9 11.1 3.9 
Cleaner 15.8 3.2 13.3 2.9 15.4 3.6 
Meals on Wheels 2.3 3.4 2.4 3.9 1.7 3.2 
Laundry service 2.5 3.6 2.1 3.6 1.4 4.3 
Sitting service 1.4 3.7 1.0 4.1 1.4 3.6 
Carer’s support worker 2.0 3.7 1.1 4.2 1.5 3.6 
Personal assistant 1.2 3.5 1.6 4.1 1.5 3.8 
Day care 1.3 3.6 1.0 4.2 1.7 3.6 
Psychosocial support 
CST 0.1 3.4 0.6 2.6 2.0 2.6 
Music/dance therapy 0.5 3.6 0.5 2.6 1.0 2.7 
Animal assisted therapy 0.2 3.6 0.5 2.8 0.2 3.2 
Social engagement 
group 7.1 3.5 6.0 2.6 8.0 3.1 
Walking group 0.8 3.6 0.2 2.8 1.0 3.1 
Life story work 0.2 4.0 0.3 2.8 0.5 3.2 
Peer support group 0.5 3.5 0.3 2.9 1.0 2.9 
Befriending service 1.2 3.7 0.6 2.8 1.4 2.9 
Memory Café 0.9 3.5 1.6 2.6 3.1 3.4 
Psycho-education 0.1 4.1 0.0 2.9 0.0 3.6 
Reminiscence therapy 0.3 3.4 1.0 3.1 0.5 3.6 
Other 5.8 N/A 7.5 N/A 6.0 N/A 
SALT – Speech and Language Therapist; CST – Cognitive Stimulation Therapy 
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Table 2: MAS staffing levels and patient throughput 
 Missing  Mean Median Range 
WTE doctors 8 1.77 1.40 0.1-8 
WTE nurses 8 3.81  2.82 0.6-10.35 
WTE psychologists 8 0.91 0.71 0-5.49 
WTE allied health professionals 8 0.81 0.71 0-3.6 
WTE advice & support workers 8 0.94 0.71 0-7.05 
WTE administrators 8 1.85 1.41 0-5.83 
Patients assessed per month 1  48.28 45 10-130 
WTE – whole time equivalent 
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Table 3: Costs associated with MAS 
 Mean (£) SD (£) Median (£) IQR (£) 
Monthly costs of a MAS     
Imaging 3,482 4,645 1,844 5,316 
Assessment * 33,697 27,348 26,684 26,793 
Post diagnosis support* 17,833 14,784 14,415 12,403 
Follow-up* 21,193 16,154 18,133 21,569 
Total 76,206 46,921 66,866 48,319 
Monthly cost per new patient     
Assessment (including imaging)*  898 755 740 741 
Post diagnosis support*  427 355 360 376 
Follow-up*  531 497 383 503 
Total  1,855 1,221 1,574 1,436 
*costs include a proportion of administration, management and audit costs 
Note: mean costs per patient assessed are means of ratios and hence do not equate to ratios of the mean costs and the mean number of new patients 
assessed. 
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Table 4: Cost of care and services received outside MAS reported by carers over previous one month at baseline and follow-up 
 Baseline (£) 3 month follow-up (£) 6 month follow-up (£) 
 Mean Median Range Mean Median Range Mean Median Range 
Health care 60 0 0 - 6,906 30 0 0 - 551 59 2 0 - 894 
Social care 69 0 0 - 3,360 92 0 0 - 5,428 154 0 0 - 7,200 
Psychosocial  
support 
11 0 0 - 1,372 4 0 0 - 336 11 0 0 - 672 
Social security 
benefits 
125 0 0 - 609 130 0 0 - 609 166 12 0 - 609 
Informal care 1,493 1,415 0 - 4,032 1,527 1,344 0 - 3,984 1,621 1,344 0 - 4,032 
          
Total cost of formal 
care 
141 1 0 - 10,471 127 1 0 - 6,086 224 19 0 - 8,016 
Total societal cost 1,637 1,565 0 - 13,162 1,658 1,362 0 - 8,792 1,847 1,462 0 - 10,699 
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Table 5 Mean (SD) of projected costs of diagnosis and support per patient for patients attending MAS over six months from 
assessment (£). 
  Proportion of all post-diagnostic support costs accrued at six months  
  0% 25% 50% 75% 100% 
Proportion of 
all follow-up 
costs 
accrued at 
six months  
0% 1,582 (2,571)  1,689 (2,602) 1,796 (2,635) 1,904 (2,672) 2,011 (2,710) 
25% 1,703 (2,590) 1,811 (2,622) 1,918 (2,656) 2,025 (2,692) 2,132 (2,732) 
50% 1,825 (2,615) 1,932 (2,646) 2,039 (2,681) 2,147 (2,718) 2,254 (2,758) 
75% 1,946 (2,644) 2,054 (2,676) 2,161 (2,711) 2,268 (2,748) 2,375 (2,788) 
100% 2,068 (2,678) 2,175 (2,710) 2,282 (2,745) 2,390 (2,783) 2,497 (2,823) 
Median and Interquartile range available from the authors on request. 
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Figures 
 
 
Figure 1. Distribution of total monthly costs per new patient assessed across clinics 
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Figure 2.  The distribution of health and social care costs reported by carers at baseline, 
three and six months (plots truncated at £2,000) 
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